On a mission to
transform the future
of autoimmune care
Developing innovative therapies with the potential to redefine
the standard of care for autoimmune diseases.
Who We Are Jade
Jade
Biosciences
We are developing a pipeline of potentially best-in-class therapies aimed at transforming the standard of care for patients living with autoimmune diseases. Our programs build on discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Jade’s lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug-enabling studies underway and first-in-human trials expected to initiate in the second half of 2025.